Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 92,023 Shares

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 92,023 shares of the company’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $29.67, for a total transaction of $2,730,322.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, October 21st, Ra Capital Management, L.P. sold 25,027 shares of Vor Biopharma stock. The stock was sold at an average price of $28.11, for a total transaction of $703,508.97.
• On Friday, October 17th, Ra Capital Management, L.P. sold 260,859 shares of Vor Biopharma stock. The stock was sold at an average price of $29.39, for a total transaction of $7,666,646.01.
• On Thursday, October 16th, Ra Capital Management, L.P. sold 151,803 shares of Vor Biopharma stock. The stock was sold at an average price of $29.45, for a total transaction of $4,470,598.35.
• On Wednesday, October 15th, Ra Capital Management, L.P. sold 51,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.55, for a total transaction of $1,569,139.65.

Vor Biopharma Price Performance

Shares of NASDAQ:VOR opened at $26.50 on Thursday. Vor Biopharma Inc. has a 52-week low of $2.62 and a 52-week high of $65.80. The stock has a fifty day moving average of $35.96. The stock has a market capitalization of $181.53 million, a price-to-earnings ratio of -0.10 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR) last announced its earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Analyst Upgrades and Downgrades

Several research firms have issued reports on VOR. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Vor Biopharma in a research report on Thursday, August 14th. Baird R W upgraded shares of Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. Wedbush restated an “outperform” rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a research report on Wednesday, September 24th. Finally, Wall Street Zen lowered shares of Vor Biopharma to a “strong sell” rating in a research report on Saturday, June 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $77.83.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds and other institutional investors have recently modified their holdings of VOR. Jane Street Group LLC bought a new position in shares of Vor Biopharma during the first quarter valued at about $140,000. OMERS ADMINISTRATION Corp bought a new position in shares of Vor Biopharma during the first quarter valued at about $100,000. Ariose Capital Management Ltd bought a new position in shares of Vor Biopharma during the third quarter valued at about $5,368,000. Goldman Sachs Group Inc. raised its stake in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Vor Biopharma during the second quarter valued at about $66,000. 97.29% of the stock is owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.